Bellecapital International Ltd. trimmed its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,654 shares of the company’s stock after selling 305 shares during the period. Bellecapital International Ltd.’s holdings in Eli Lilly and Company were worth $2,183,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in LLY. Norges Bank bought a new position in Eli Lilly and Company in the 4th quarter valued at about $3,416,206,000. Moneta Group Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 102,752.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares in the last quarter. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after buying an additional 3,691,436 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in Eli Lilly and Company by 316.9% during the first quarter. Envestnet Asset Management Inc. now owns 2,434,073 shares of the company’s stock worth $217,569,000 after buying an additional 1,850,187 shares in the last quarter. Finally, Mizuho Markets Americas LLC raised its position in Eli Lilly and Company by 2,882.6% in the 1st quarter. Mizuho Markets Americas LLC now owns 1,765,702 shares of the company’s stock valued at $18,090,000 after buying an additional 1,706,502 shares during the last quarter. 81.38% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have issued reports on LLY. Argus lifted their price objective on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 9th. Citigroup increased their price objective on shares of Eli Lilly and Company from $360.00 to $525.00 and gave the company a “buy” rating in a research note on Wednesday, July 26th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $510.00 to $600.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. Finally, Jefferies Financial Group raised Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their price target for the company from $408.00 to $615.00 in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $532.78.
Eli Lilly and Company Trading Down 2.7 %
NYSE:LLY opened at $575.66 on Friday. Eli Lilly and Company has a 1 year low of $296.32 and a 1 year high of $601.84. The stock’s fifty day moving average price is $510.09 and its two-hundred day moving average price is $435.73. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The company has a market cap of $546.47 billion, a P/E ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The business had revenue of $8.31 billion for the quarter, compared to analysts’ expectations of $7.58 billion. During the same quarter in the prior year, the firm posted $1.25 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 9.84 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.
Insiders Place Their Bets
In related news, EVP Alonzo Weems sold 1,148 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the transaction, the executive vice president now directly owns 7,760 shares in the company, valued at $4,586,004.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the transaction, the executive vice president now owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 34,156 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the sale, the insider now owns 101,387,286 shares in the company, valued at approximately $46,037,938,826.88. The disclosure for this sale can be found here. Insiders have sold 1,010,309 shares of company stock worth $21,095,701,670 in the last three months. 0.13% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Five stocks we like better than Eli Lilly and Company
- How to Invest in EV Charging Stations
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 9/11 – 9/15
- Investing in Travel Stocks Benefits
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.